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The complemental DNAs encoding human interferon-y (IFN-y) and human interleukin-2 (IL-2), two dif- 
ferent proteins involved in the same immune system, were fused to code a hybrid protein, which was ex- 
pressed in E. co& to investigate the interactions of these two proteins at the molecular level. Through immu- 
noprecipitation analysis, this protein was revealed to be of about 31 kDa, which was expected from nucleo- 
tide sequencing, and to have the antigenicities of both IFN-y and IL-2. The extract from bacteria expressing 
this hybrid protein showed at least two biological activities: an antiviral activity derived from IFN-7 and 
the ability to support the growth of natural killer (NK) cells derived from IL-2. Comparing the enhancement 
of NK cell activity of this hybrid protein with IFN-y and IL-2, this hybrid protein appears to conserve each 
activity almost completely without diminishing the other. 
complementary DNA Interferon-y Interleukin-2 Hybrid protein Antigenicity 
Integrated biological activity (Human) 
1. I~RODUCTION 
Both human interferon-y (1FN-y) and human 
interleukin-2 (IL-2), glycoproteins of approx. 17 
and 15 kDa, respectively, are produced by T cells 
stimulated with mitogens or antigens. 
IFN-y has anti-viral and anti-proliferative activi- 
ty, enhances the activity of natural killer (NK) cells 
and modulates the various functions of macro- 
phages [l]. IL-2 has the ability to support the long- 
term growth of T and NK cells in vitro, and 
augments the activity of killer cells including 
cytotoxic T cells, NK cells and lymphokine-acti- 
vated killer cells [2,3]. 
Thus, while the various activities of these two 
glycoproteins seem to collaborate with or an- 
tagonize each other, they appear d~endently in- 
volved in the immune system. IL-2 was reported to 
regulate the synthesis of IFN-y by T cells [4], and 
both IFN-y and IL-2 are required to induce cyto- 
toxic T cells [3,5]. Furthermore, IL-Zinitiated 
events, such as boosting NK activity, are IFNT- 
dependent [3,5]. Recently, the effects of the two 
proteins on B cells as well as on T cells were 
demonstrated independently: IFN-7 directly dif- 
ferentiates resting B cells to immunoglobulin- 
secreting cells [6] and IL-2 induces the prolifera- 
tion of Sta~~yiococc~s aureus Cowan I activated B 
cells [7]. 
2. MATERIALS AND METHODS 
Complementary DNAs (cDNAs) for both IFN-y 
and IL-2 were obtained by cDNA cloning [1,2]. 
IFNy cDNA (I kbp) cut out from clone pHIT3709 
was inserted into the ClaI-PstI portion of ptrp771 
using C/a1 adapter. The resulting pHITtrp1101 
codes for an IFN-y with Met-Cys-Tyr at its 
NH*-terminus. The 477-bp fragment of IL-2 
cDNA prepared from pILOT135-8 was cloned 
once into ptrp781 using EcoRI adapter. Then the 
442-bp fragment coding IFN-y lacking 11 amino 
acid residues at its COOH-terminus was purified 
and ligated to the 589-bp fragment prepared from 
pTF1 using EcoRI linker. This ligated DNA 
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coding for a hybrid protein was inserted into the 2.2. Preparation of cell extracts and assays for 
Clai-PstI portion, downstream of the trp pro- biologicaI activities 
moter, of ptrp771 to construct pIFL9906 (fig.la). Bacterial cultures of DHl cells transformed by 
a 
T4 DNA lig. J 
HpaI 
----------I 1 EcoRI linker, 
T-z, lig. 1 
I ClaI,EcoRI 
MetAlaPro 
1 4 EcoRI,PstI 
T4 DNA lig. 
l 
589-bp 
NetcysTyrcys ArgSerProGlitPheMetAlaPro ThrLeuTht - 
--ATGTGTTACTGC--AGGAGTCCGGAA~AT~~CCT--ACACTAACTTGA-- 
T4 DNA lig. 
1 
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ChI 
PheAsoAlsClyHisSerAspYalAlaAs~AsnGlyThrLeuFhe~euGlyIleLeuLys 
TTTAATGCAGGTCATTCAGATGTAGCGGATAATGGAACTCTTTTC~AGGCATTTTGAAG 
CluAspWetAsnVslLrsPhePheAsnSerAsnLysLYs~~PheGluLys %3 
GAAGACATCAATCTCAAGTTTTTCAATAGCAACAAAAAGAAACGAGA~ACTTCGAAAAG 298 
GlnWslWetAlaCluLeuSerProAtsllaLrs'fhrGlyLysAr~LysAr~SerProGlu 
CAAGnATGGCfGAACTGTrGCCAGCAGETAAAA~AGGGAAGCGAAAAAGGAG~CGGAA 
IFN-ssmur W- 
PhaWetAlaProThrSerSerSerTkrLrsLysThrGlnLeuGlnLeuGluHisLeuLeu 
nTATGGCACCTAC~CAAGTTCTACAAAGAAA~ACAGCTACAACTGGAGCATTTACTG 
--IL-z 
LeuAspLeuGlnWetlleLeuAsnGtrileAs~AsnTyrLysAsnProLysLeuTkrAr~ 
CTGGATTTACAGATGATTTTGAATGGAATTAATAATTACAAGAA~CCAAACTCACCAGG 
118 
358 
138 
418 
158 
478 
178 
538 
198 
596 
216 
658 
238 
718 
259 
778 
273 
838 
896 
906 
UetLeuTkrPheLysPkeTyrYetProLysLysAlaThrGluLeuLysHisLeuGlnCys 
ATCCTCACATTTAAGTTTTACATGCCCAAGAAGGCCACAGAACTGAAACATCTTCAGTGT 
LeuGluGluGluLeuLysProLeuGluGluValLeuAsnLeuAl~GlnSerLysAsnPhe 
CTAGAAGAAGAACTCAAACCTCTGGAGGAAGTGCTAAATTTAGCTCAAAGCAAAAACTTT 
HisLeuAraProArsAspLeuIleSerAsnlleAsnValIleVlrlLeuGluLeuLysGIr 
CACTTAAGACCCACGCACTTAATCAGCAATATCAACGTAATAGTTCTGGAACTAAAGGGA 
CCCTGCAG-3' 
Pstl 
Fig.l.(a) Construction of plasmids that express the 
hybrid protein. See section 2.1 for details. (b). 
Nucleotide sequence of fused cDNAs of IFNr and IL-2 
and predicted amino acid sequence of the hybrid pro- 
tein. The hybrid protein consists of 1FN-y (lacking 11 
amino acid residues from its COOH-terminus) and IL-2 
with an intervening sequence of Pro-Glu-Phe-Met 
b 
18 
58 
(underlined). 
different plasmids were grown as described [8]. 
The cells were harvested, suspended in l/IO vol. 
buffer (100 mM Tris-Cl, pH 7.0; 7 M guanidine 
HCl, 2 mM phenylmethylsulfonyl fluoride), and 
incubated for 1.5 h at 0°C. After dialysis vs buffer 
(10 mM Tris-Cl, pH 8.5; 200 mM NaCl, 1 mM ED- 
TA), the cell-free extracts were assayed in 
duplicate on human FL amnion cells and Sindbis 
virus system for IFN-7 activity and on an IL-2- 
dependent mouse cell line, NKC3, using a [3H]- 
thymidine incorporation assay [2] for IL-2 activity. 
2.3. rrnrnun~pr~~ipi~at~o~ a~uiys~ 
E. coli containing each plasmid was grown and 
the cells labelled with t3%]Met 181. Cell extracts 
were imm~noprecipitated with rabbit antibody, 
absorbed with staphylococcal absorbent and ana- 
lyzed using SDS-polyacrylamide gel electrophoresis 
PI. 
2.4. Cytotoxicity assay 
A natural cell-mediated cytotoxicity assay was 
performed as in [lo]. Human K562 cells in com- 
plete minimal essential medium (CMEM) were 
labelled with Naz”Cr04 and human peripheral 
blood mononuclear cells (PBMC) used as effector 
cells. PBMC were cultured in CMEM with each 
agent. Samples of srCr-labelled tumor cells were 
added to triplicate samples of effector cells (effec- 
tor to target ratios varied from 100: 1 to 12.5 : 1) in 
round-bottomed microtiter plates. After appro- 
priate incubation, the supernatants were harvested 
and counted in a gamma counter. 
3. RESULTS AND DISCUSSION 
Using cDNA clones, we constructed the plasmid 
pHITtrpl101 for expressing IFNy and pTF1 for 
IL-2 under the control of the E. edi trp promoter 
(fig.la). These plasmids encode the entire IFN-y 
and IL-2 proteins, both of which have methionines 
replacing the signal peptides. With these two 
plasmids we constructed plasmid pIFL9906, which 
expresses the hybrid protein (fig.la). The hybrid 
protein encoded by this plasmid consists of 137 
amino acid residues derived from the IFN-y in its 
NHz-terminal side and 134 amino acid residues 
derived from IL-2 in its COOH-terminal side 
across 3 amino acid residues derived from a 1Zmer 
EcoRI linker (fig. 1). 
Analysis of [3sS]Met-labelled total cell extracts 
from the E. co/i cells harbouring pHITtrpllO1, 
pTF1 and pIFL9906 on SDS-polyacrylamide gels 
showed an induced recombinant IL-2 (rIL-2) of 15 
kDa, a recombinant IFN+y (rIFN+ of 17 kDa and 
the hybrid protein of 31 kDa (fig.2, lanes 4,7,5). 
Through immunoprecipitation analysis with anti- 
rIFN-y antibody and anti-rIL-2 antibody, the 
hybrid protein was immunoprecipitated with both 
antibodies while rIFN-y expressed by pHITtrp 1101 
and rIL-2 expressed by pTF1 were each immuno- 
precipitated with only one antibody. Each im- 
munoprecipitat~ protein is shown as a single band 
analyzed on the SDS-polyacryl~ide gel (fig.2, 
lanes 1,2,8,10). 
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1 23 4 5 6 7 8 SW11 Table 1 
Fig.2. Autoradiogram of SDS-polyacrylamide gel. Cell 
extracts, immunoprecipitated with rabbit antibody and 
absorbed with staphylococcal absorbent, labelled with 
[‘?S]Met were analyzed on 17.25% SDS-polyacrylamide 
gel electrophoresis. Lanes: 1 - 3, protein immuno- 
precipitated with anti-rIL-2 antibody; 1, pTF1; 2, 
pIFL9906; 3, ptrp771; 4-7, total cell extracts; 4, pTF1; 
5, pIFL9906; 6, ptrp771; 7, pHITtrpllO1; 8-10, proteins 
immunoprecipitated with anti-rIFN-y antibody: 8, 
pIFL9906; 9, ptrp771; 10, pHITtrpllO1; 11, molecular 
mass markers (lysozyme, 14.3 kDa; carbonic anhydrase, 
30 kDa; ovalbumin, 46 kDa; bovine serum albumin 69 
kDa; phosphorylase b, 92.5 kDa). 
These extracts from E. coli were assayed for 
IL-2 and IFN-y activity. The extract from 
pIFL9906 contained about lo6 IU IFN-7 activity/l 
bacterial culture and 104 U IL-2 activity in equi- 
valent culture, while that from pHITtrpllO1 con- 
tained 3 x lo* IU and that from pTF1 10’ U/l 
bacterial culture (table 1). 
The hybrid protein expressed by pIFL9906 has 
not only the antigenicities of IFN-7 and IL-2 but 
also the activities of both. 
We have purified rIFN-y and the rIL-2 using 
pHITtrp1101 and pTF1 or some other derivatives, 
and concluded that 1 mg IFN-7 has about 4 x lo6 
IU and 1 mg IL-2 about 4 x lo4 U. From these 
values the ratio of the activities between equimolar 
IFN-y and IL-2 is calculated as 
(IFN-7 activity/IL-2 activity) = 
6.8 x 1013/6x 10” = 113 
Biological activities of the hybrid protein produced in E. 
coli 
Clone IFN-7 activity IL-2 activity 
(III/l broth) (U/l broth) 
pIFL9906 1.2 x lo6 1.1 x lo4 
pHITtrp1101 300.0 x lo6 0 
pTF1 0 12.0 x 104 
Cell-free extracts were assayed in duplicate on human 
FL amnion cells and Sindbis virus system for IFNy ac- 
tivity and on an IL-Zdependent mouse cell line, NKC-3, 
using a [3H]thymidine incorporation assay [2] for IL-2 
activity 
the molecular mass of 1FN-y and IL-2 being 17 and 
15 kDa, respectively. This facilitates estimation of 
the ratio of activities in a molecule of the hybrid 
protein. From table 1 the ratio is calculated as 
(IFN-Y activity/IL-2 activity)hybrid =
1.2 x 106/1.1x104 = 109 
This value is almost equal to that calculated above, 
which probably means that this hybrid protein 
totally conserves the activities of both IFN-y and 
IL-2. 
This estimation was also supported by the en- 
hancement of NK cell activity (fig.3). The enhance- 
ment was almost equal to that of rIFN-y and rIL-2 
together; this reflects the derived values, 113 and 
109. 
We made the 11 deleted amino acid residues 
from the COOH-terminus of IFN-7 to design this 
hybrid protein for the convenience of ligating the 
DNA fragments. We knew that this deletion did 
not affect the IFN-7 activity (not shown). Based on 
data already presented, the influence on the ac- 
tivities and antigenicities of the hybrid protein of 
the intervening sequence of 4 amino acid residues, 
Pro-Glu-Phe-Met, derived from the linker and 
adaptor (fig.la), appeared negligible. Whether 
these bifunctional activities and antigenicities 
would be maintained in other hybrid proteins of 
the NHz-[IL-2]-[IFN-y]-COOH type including the 
intervening sequence is unknown. 
The significance of such a multifunctional hybrid 
protein is as follows. Cells that have IL-2 (IFN-7) 
receptor but no IFN-y (IL-2) receptor can accept 
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Effector cell to tweet cell ratio 
Fig.3. Enhancement of NK cell activity. Human KS62 
cells were labelled with Naz”Cr04 and human PBMC 
were used as effector cells. The PBMC were cultured in 
CMEM with 0.1 U rIL-2 from E. cofi containing pTF1 
(m), 10 IU r1FN-y from E. coli containing pHITtrp1101 
(A), hybrid protein equivalent to each activity of rIL-2 
and r1FN-y from E. coli containing pIFL9906 (0), both 
0.1 U rIL-2 and 10 IU rIFNy (o), and no agents (0). 
The percent specific cytotoxicity was calculated as 
[[(cpm experimental “Cr release) - (cpm spontaneous 
‘lCr release)J/[(cpm maximum ‘lCr release) - (cpm 
spontaneous ‘lCr release)]] x 100. 
IL-2 (IFN-y) molecules and response reflecting 
some effects by IL-2 (IFN-y) activity but cannot 
accept IFN-y (IL-2) lacking its receptor. These 
cells will accept the hybrid molecule exhibiting 
some responses as the results of both IL-2 and 
IFN-y activity. The mechanisms of the reaction 
between the factors and their receptors and of the 
post-reaction processing are still obscure, however, 
the hybrid protein can be used to investigate 
lymphokine-receptor mechanisms. Furthermore, 
this kind of hybrid molecule may have clinical ap- 
plication. 
The possibility of constructing multifunctional 
proteins is also interesting from the stereochemical 
point of view. The hybrid protein may be con- 
sidered to be a proteinconsisting of two active do- 
mains [l l] derived from IFN-y and IL-2 because 
its predicted amino acid sequence (fig.lb) is com- 
plete enough to divide it into two domains, one for 
each active site. Although it is probable that this 
hybrid protein is a bifunctional protein with two 
active domains, it might be possible to construct a 
bifunctional protein with two active sites in one 
domain, i.e. a hybrid molecule consisting of one 
skeletal structure derived from either IFN-y or 
IL-2 with two activities from the two immunolo- 
gical factors. This type of trial, which is in progress 
in our laboratory, will minimize the M, and thus 
make more active proteins in vivo avoiding im- 
munological attack. There are successful reports of 
protein engineering by ‘site-directed mutagenesis’, 
which involves replacing the amino acid composi- 
tion of a protein to obtain more powerful activities 
and/or stabilities or different activities [ 12,131. 
Our way of creating the hybrid protein, by genetic- 
ally fusing two proteins, is another way of engi- 
neering new useful proteins that are multifunc- 
tionally active. Creating such hybrid proteins is ex- 
pected to be a powerful strategy for protein en- 
gineering in the future. 
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